<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576249</url>
  </required_header>
  <id_info>
    <org_study_id>15-003120</org_study_id>
    <nct_id>NCT02576249</nct_id>
  </id_info>
  <brief_title>Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis</brief_title>
  <official_title>Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corticosteroid injections are commonly used for the symptomatic treatment of knee
      osteoarthritis. Common practice is to inject the joint with a combination of corticosteroid
      and local anesthetic, with the rationale of providing longer duration pain relief with the
      corticosteroid and immediate, though short duration relief with the anesthetic. However,
      multiple in vitro and animal studies have shown that local anesthetic may be harmful to
      chondrocytes. Despite this data, use of intra-articular anesthetic remains widespread. Many
      clinicians believe incorporating the anesthetic is important because it can provide
      immediate pain relief and facilitate patient confidence in the treatment program. However,
      there is no published data to validate this reasoning. Therefore, the anesthetic has unknown
      clinical benefit and may have adverse effects on articular cartilage. In light of this, the
      investigators question the routine use of anesthetics in joint injections. The purpose of
      this study is to compare the effects of knee joint injections using: 1) corticosteroid with
      local anesthetic versus 2) corticosteroid with normal saline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS-Pain</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2% ropivacaine and methylprednisolone knee joint injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.9% normal saline and methylprednisolone knee joint injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% ropivacaine</intervention_name>
    <arm_group_label>ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% normal saline</intervention_name>
    <arm_group_label>saline</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. age 18 or older

          2. knee osteoarthritis (uni- or bilateral) as defined by the American College of
             Rheumatology (staged by Kellgren-Lawrence radiographic grading scale)

        Exclusion criteria:

          1. rheumatologic/inflammatory disease

          2. metabolic bone disease

          3. crystalline arthropathy

          4. current smoking

          5. BMI &gt; 40

          6. knee injection with corticosteroid or viscosupplementation within previous 6 months

          7. history of knee prolotherapy, platelet rich plasma or cellular (stem cell) injection

          8. knee surgery within the last year

          9. chronic opioid use

         10. chronic pain syndrome/fibromyalgia

         11. pain behavior during the clinical encounter as judged by the injecting physician

         12. physician specifically orders injection of corticosteroid/anesthetic or other
             specific combined corticosteroid injection

         13. diagnostic uncertainty by referring provider

         14. referral for bilateral knee or multiple joint injections (*note that arthritis
             involving multiple joints alone is not an exclusion criteria, only the patient
             receiving more than 1 injection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob L Sellon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>October 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jacob L. Sellon, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>injection</keyword>
  <keyword>steroid</keyword>
  <keyword>anesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
